Cellectis (NASDAQ:CLLS)‘s stock had its “neutral” rating reaffirmed by analysts at Guggenheim in a research report issued on Tuesday, Benzinga reports.
CLLS has been the subject of a number of other research reports. Zacks Investment Research raised shares of Cellectis from a “sell” rating to a “hold” rating in a research report on Monday, February 8th. Robert W. Baird reaffirmed a “buy” rating and issued a $39.00 target price on shares of Cellectis in a research report on Thursday, April 29th. Finally, William Blair reaffirmed an “outperform” rating on shares of Cellectis in a research report on Monday, March 8th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $31.00.
Shares of CLLS stock opened at $18.16 on Tuesday. The firm has a fifty day moving average of $19.69 and a 200-day moving average of $23.33. The company has a quick ratio of 6.00, a current ratio of 6.11 and a debt-to-equity ratio of 0.10. Cellectis has a 12-month low of $13.08 and a 12-month high of $34.71. The company has a market capitalization of $825.46 million, a price-to-earnings ratio of -9.66 and a beta of 2.59.
A number of institutional investors have recently modified their holdings of the business. Nikko Asset Management Americas Inc. raised its position in shares of Cellectis by 15.1% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 890,511 shares of the biotechnology company’s stock valued at $17,997,000 after buying an additional 116,723 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Cellectis in the first quarter worth about $39,000. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Cellectis by 15.1% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 890,511 shares of the biotechnology company’s stock worth $17,997,000 after purchasing an additional 116,723 shares during the last quarter. OneAscent Financial Services LLC raised its position in shares of Cellectis by 11.0% in the 1st quarter. OneAscent Financial Services LLC now owns 12,294 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 1,214 shares during the last quarter. Finally, OneAscent Wealth Management LLC raised its position in Cellectis by 11.9% in the 1st quarter. OneAscent Wealth Management LLC now owns 26,377 shares of the biotechnology company’s stock worth $533,000 after buying an additional 2,799 shares during the last quarter. Institutional investors and hedge funds own 33.30% of the company’s stock.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.
Further Reading: Why is total return important?
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.